Home » Investors » Press Releases » Cellenion Announces Opening of BICO’s First Single Cell Analysis Centre of Excellence

Single Press release

Cellenion Announces Opening of BICO’s First Single Cell Analysis Centre of Excellence

March 3, 2022 2:00 pm
Cellenion will provide a range of comprehensive single cell analyses and handling services from its new state-of-the-art laboratories in Lyon.

Cellenion, a  BICO company, announced today the opening of the BICO group’s first Single Cell Analysis Centre of Excellence at its facilities in Lyon. This state-of-the-art centre will offer a range of services (cellenSERVICES) to companies and academic groups seeking complete solutions for their single cell projects from tissue dissociation to single cell isolation, library preparation, sequencing and subsequent bioinformatic analyses.

Cellenion has developed cellenONE®, a unique single cell isolation and nanoliter dispensing technology allowing high throughput image-based dispensing of individual cells from cell suspensions and precision dispensing of reagents to automate and miniaturize sample preparation prior to single cells analyses. By opening this service, Cellenion will offer its unique technology platform and strong expertise in the field of single cell isolation and sample preparation to a much wider public.

Dr. Guilhem Tourniaire, Managing Director of Cellenion, said, “We believe that by offering access to our technology through a panel of dedicated services, we will be able to answer a growing demand in the Biopharma and cosmetic industries for reliable and complete solutions in single cell analyses.”

Dr. Holger Eickhoff, CEO of Cellenion, said “by combining a very strong single cell expertise with our unique cellenONE technology from our facilities in France, we aim to capture new customers seeking timely and comprehensive analyses of their clinical or research samples while using data storage exclusively located in Europe to ensure the highest security around the data generated.”

Initially focussing on single cell transcriptomic analyses using cellenONE, Cellenion plans to diversify its offering to other areas of expertise such as automated cloning for cell line development and sorting and isolation of 3D cellular aggregates (spheroid and organoids) using its recently launched, spheroONE. 

For more information on Cellenion’s services, please visit: www.cellenion.com/services

For further information, please contact:

Avijit Minocha, Head of Marketing, BICO

Phone (US): +1 (617) 637 5372
Email: akm@bico.com  

This information was submitted for publication, through the agency of the contact persons set out above, on March, 3, 2022 at 14:00 (CET).

About Cellenion

Cellenion offers solutions and technologies for controlled cell dispensing with applications in the fields of single cell and single cellular aggregates isolation. Our systems allow high throughput, image-based automated dispensing of single cells and/or cell aggregates onto any substrates of choice. Together with a range of dedicated consumables, the solutions enable miniaturization of sample preparation protocols on the same instrument before downstream analysis. With no dead volumes and outstanding recovery rates, Cellenion’s platforms offer unique capacities for applications including single-cell omics, rare cells, cell line development, drug screening and 3D model development. Cellenion operates from Lyon, France. The company is a subsidiary of SCIENION GmbH and its products are sold by SCIENION worldwide.

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better.

With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.

The Group’s products are trusted by more than 25,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.